Lower jaw osteonecrosis associated with bisphosphonates.
DOI:
https://doi.org/10.35954/SM2023.42.1.7.e402Keywords:
Diphosphonates, Mandible, Maxilla, Dentistry, Osteonecrosis, Bisphosphonate-Associated Osteonecrosis of the JawAbstract
Introduction: Given the high prescription of bisphosphonates, we present their adverse effects in the dental sphere, being an infrequent complication, but difficult to treat. There is no need to suspend treatment, given the important benefit in terms of prevention of fragility fractures. These fractures cause high morbimortality as opposed to the low risk associated with bisphosphonate-associated osteonecrosis of the jaw.
Objective: To orient the health personnel who handle these drugs and who assist these complications to have knowledge for the prevention of osteonecrosis. To identify and differentiate patients at higher risk, according to the dose of bisphosphonates and frequency of treatment.
Materials and Method: A literature review was performed in the following sources: Scielo, Google academic, Medline/Pubmed, Virtual Health Library (Brazil), from 2005 to date, Spanish, Portuguese and English languages. The descriptors used were bisphosphonates, mandible, maxilla, dentistry, osteonecrosis, osteonecrosis of the jaws associated with bisphosphonates.
Results: The latest treatment guidelines were modified in 2014, by consensus of the American Association of Oral and Maxillofacial Surgery. The pathogenesis of bisphosphonate-associated maxillary osteonecrosis is not completely defined, although publications try to explain it. The risk of developing it by oral therapy is lower than by intravenous administration. Discussion: The physician who prescribes the antiresorptive drug should know the dental health status of his patient and, if possible, refer him for examination by a dentist before initiating bisphosphonate therapy.
Received for evaluation: September 2022.
Accepted for publication: February 2023.
Correspondence: Grupo "Las Piedras" de artillería 105 mm Nº 3. General Manuel Oribe 502. Paso de los Toros, Tacuarembó, Uruguay. Tel: (+598) 4664 2235 - Fax: 4664 2374.
E-Mail contact: gpoa3@ejercito.mil.uy
Downloads
Metrics
References
(1) Asociación Colombiana de Osteoporosis y Metabolismo Mineral (ACOMM). I Consenso Colombiano de osteonecrosis de los maxilares asociada a medicamentos, 2020; 25 p. Disponible en: https://asociacioncolombianadeosteoporosis.com/wp-content/uploads/2020/10/Consenso-colombiano-osteonecrosis-mandibular-1.pdf [Consulta 22/07/2022]
(2) Giribone J, Catagnetto P. Osteonecrosis de los maxilares inducida por bifosfonatos: lo que el odontólogo debe saber hoy: pautas y protocolos. Odontoestomatología 2013; (21):45-58. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S168893392013000100006&lng=es [Consulta 22/07/2022]
(3) Renom S. Bifosfonatos. Osteonecrosis de los maxilares asociado a medicamentos antirresortivos. Diagnóstico y tratamiento. Monografía presentada como trabajo final del título de Especialista en Cirugía y Traumatología Buco Maxilofacial. Universidad de la República, Facultad de Odontología, Montevideo Uruguay. 2016. Actualización 2020.
(4) Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 2007; 12(4):336-40. PMID: 17664922.
(5) Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9):1115-7. doi: 10.1016/s0278-2391(03)00720-1. DOI: https://doi.org/10.1016/S0278-2391(03)00720-1
(6) American Association of Oral and Maxillofacial Surgeons. AAOMS position paper renames and expands the scope of Bisphosphonate Related Osteonecrosis of the Jaw – now Medication Related Osteonecrosis of the Jaw (MRONJ), 2014. [Internet]. Available from: https://www.aaoms.org/news/aaoms-position-paper-renames-and-expands-the-scope-of-bisphosphonate-relate [Consulted 22/07/2022].
(7) Jimenez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update. Med Oral Patol Oral Cir Bucal 2005; Suppl 2:88-91. PMID: 15995577.
(8) Guelman R, Silvia Larroudé M, Mansur J, Sánchez A, Vega E, Zanchetta M, et al. Definición de osteonecrosis maxilar. Osteonecrosis de los maxilares asociada a medicamentos. Actual. Osteol 2020; 16(3):232-252. Disponible en: http://www.osteologia.org.ar [Consulta 22/07/2022]
(9) Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, et al. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. J Clin Endocrinol Metab 2022 Apr 19; 107(5):1441-1460. doi: 10.1210/clinem/dgab888. DOI: https://doi.org/10.1210/clinem/dgab888
(10) Soma T, Iwasaki R, Sato Y, Kobayashi T, Ito E, Matsumoto, et al. Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics. Scientific Reports 2022; 12(1):19. doi: 10.1038/s41598-021-03966-6. DOI: https://doi.org/10.1038/s41598-021-03966-6
(11) Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int. 2016; 27(3):853-859. doi: 10.1007/s00198-015-3335-3. DOI: https://doi.org/10.1007/s00198-015-3335-3
(12) Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Int J Bone Mineral Res 2007; 22(10):1479-1491). https://doi.org/10.1359/jbmr.0707onj DOI: https://doi.org/10.1359/jbmr.0707onj
(13) Diaz-Reverand SA, Naval-Gíaz L, Muñoz-Guerra MF, Sastre-Pérez J, Rodríguez-Campo F J, Gil-Diez JL. Manejo de la osteonecrosis maxilar asociada al uso de medicamentos en virtud de su estadio clínico: análisis de 19 casos. Rev Esp Cirug Oral y Maxilofac 2018; 40(3):104-111. https://doi.org/10.1016/j.maxilo.2017.06.001 DOI: https://doi.org/10.1016/j.maxilo.2017.06.001
(14) Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA J 2019; 10(1):21-29. doi: 10.1007/s13167-019-0160-3. DOI: https://doi.org/10.1007/s13167-019-0160-3
(15) Reid IR. Bisphosphonate holidays. Drug Ther Bull. 2021; 59(3):35-36. doi: 10.1136/dtb.2020.000057. DOI: https://doi.org/10.1136/dtb.2020.000057
Downloads
Published
Versions
- 2023-05-26 (2)
- 2023-05-22 (1)
How to Cite
Issue
Section
License
Copyright (c) 2023 María Noel Bertola Izquierdo, Verónica Reynolds, Luis Ignacio Rodríguez Palacio. The author retains his copyright and assigns to the journal the right of first publication of his work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License that allows sharing the work as long as the initial publication in this journal is indicated.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
